Androgenic Agents Clinical Prior Authorization Criteria Revision Scheduled for Feb. 1, 2023

December 28, 2022

HHSC will revise the clinical prior authorization criteria for Androgenic Agents on Feb. 1, 2023, to comply with Section 1557 of the Civil Rights provision of the Affordable Care Act (ACA). The ACA prohibits discrimination based on race, color, national origin, sex, disability, or age in covered health programs and activities. HHSC will revise the criteria for approval by removing step #2, which checks for the gender of the client.

This clinical prior authorization is optional for managed care. MCOs that implemented it must revise it by Feb. 1, 2023.